Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer.
The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumours, and a range of other secondary liver cancers.
David Cade, Sirtex’s chief medical officer, said: “Interventional oncology is one of the fastest growing and most exciting areas of innovation in cancer care, giving patients with few or no treatment choices, an extended lease on life while helping maintain their quality of life.”
Massimo Carrara, Guerbet’s US general manager, said: “We are looking forward to opening new horizons in interventional oncology and we are determined to explore a symbiotic clinical research partnership as we relentlessly pursue our goal to help patients with unresectable hepatic tumours.”
Guerbet and Sirtex share a common vision to advance interventional oncology by developing new approaches in patient care and treatment algorithms.
The scope of collaboration and development activities between Sirtex and Guerbet is currently being finalised, with additional announcements expected to be made in 2014, a press release states.